Dernières nouvelles pour Celularity (NASDAQ:CELU) Stock

Celularity

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from bio-banking segment.

Celularity Inc

WIIM

UPLD

Upland Software shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

Earnings

News

BSLK

Bolt Projects Holdings Q3 EPS $0.32

Golden Entertainment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDEN#NASDAQ">GDEN</a>) reported quarterly earnings of $0.18 per share which beat the analyst consensus estimate of $0.10 by 80 percent. This is a 200 percent increase over earnings of $0.06 per share from the same period last year. The company reported quarterly sales of $161.23 million which missed the analyst consensus estimate of $162.25 million by 0.63 percent. This is a 37.44 percent decrease over sales of $257.73 million the same period last year.

Earnings Beats

Earnings Misses

GDEN

Golden Entertainment Q3 EPS $0.18 Beats $0.10 Estimate, Sales $161.23M Miss $162.25M Estimate

aTyr Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATYR#NASDAQ">ATYR</a>) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.22) by 4.55 percent.

ATYR

aTyr Pharma Q3 2024 GAAP EPS $(0.23) Misses $(0.22) Estimate

Spyre Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRE#NASDAQ">SYRE</a>) reported quarterly losses of $(1.36) per share which missed the analyst consensus estimate of $(0.83) by 63.86 percent. This is a 85.44 percent increase over losses of $(9.34) per share from the same period last year.

SYRE

Spyre Therapeutics Q3 EPS $(1.36) Misses $(0.83) Estimate

Myriad Genetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYGN#NASDAQ">MYGN</a>) raises FY2024 Adj EPS guidance from $0.08-0.12 to $0.12-0.14 vs $0.10 analyst estimate. Narrows FY2024 sales outlook from $835.00 million-845.00 million to $837.00 million-843.00 million vs $841.44 million estimate.

Guidance

MYGN

Myriad Genetics Raises FY2024 Adj EPS Guidance from $0.08-0.12 to $0.12-0.14 vs $0.10 Est; Narrows FY2024 Sales Guidance from $835.00M-845.00M to $837.00M-843.00M vs $841.44M Est

LCUT

Lifetime Brands shares are trading lower after the company reported worse-than-expected Q3 financial results and lowered its FY24 guidance and Q4 EPS guidance.

SLDP

Solid Power Continues To Expect 2024 Revenue Of $16M - $20M, Est $19.783M

HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 11.76 percent.

BEAT

HeartBeam Q3 2024 GAAP EPS $(0.19) Misses $(0.17) Estimate

US Global Investors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GROW#NASDAQ">GROW</a>) reported quarterly earnings of $0.02 per share. This is a 300 percent increase over losses of $(0.01) per share from the same period last year. The company reported $2.16 million in sales this quarter. This is a 31.15 percent decrease over sales of $3.13 million the same period last year.

GROW

US Global Investors Q1 EPS $0.02 Up From $(0.01) YoY, Sales $2.16M Down From $3.13M YoY

Innovex International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INVX#NYSE">INVX</a>) reported quarterly earnings of $0.25 per share which met the analyst consensus estimate. This is a 47.92 percent decrease over earnings of $0.48 per share from the same period last year. The company reported quarterly sales of $151.82 million which beat the analyst consensus estimate of $135.00 million by 12.46 percent. This is a 9.15 percent increase over sales of $139.09 million the same period last year.

INVX

Innovex International Q3 Adj $0.25, Inline, Sales $151.82M Beat $135.00M Estimate

Eventbrite (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EB#NYSE">EB</a>) sees Q4 sales of $74.000 million-77.000 million vs $75.47 million estimate.

Eventbrite Sees Q4 Sales $74.000M-77.000M vs $75.47M Est

Tectonic Therapeutic (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TECX#NASDAQ">TECX</a>) reported quarterly losses of $(1.20) per share which missed the analyst consensus estimate of $(0.84) by 42.86 percent.

TECX

Tectonic Therapeutic Q3 2024 GAAP EPS $(1.20) Misses $(0.84) Estimate

Li-Cycle Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LICY#NYSE">LICY</a>) reported quarterly earnings of $2.15 per share which beat the analyst consensus estimate of $(1.32) by 262.88 percent. This is a 241.45 percent increase over losses of $(1.52) per share from the same period last year. The company reported quarterly sales of $8.40 million which beat the analyst consensus estimate of $6.98 million by 20.34 percent. This is a 78.72 percent increase over sales of $4.70 million the same period last year.

LICY

Li-Cycle Holdings Q3 EPS $2.15 Beats $(1.32) Estimate, Sales $8.40M Beat $6.98M Estimate

Definitive Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DH#NASDAQ">DH</a>) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $0.08 by 25 percent. This is a 11.11 percent increase over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $62.70 million which beat the analyst consensus estimate of $61.72 million by 1.58 percent. This is a 4.02 percent decrease over sales of $65.33 million the same period last year.

Definitive Healthcare Q3 Adj $0.10 Beats $0.08 Estimate, Sales $62.70M Beat $61.72M Estimate

MeridianLink (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) reported quarterly earnings of $0.06 per share which missed the analyst consensus estimate of $0.08 by 25 percent. The company reported quarterly sales of $80.369 million which beat the analyst consensus estimate of $79.969 million by 0.50 percent. This is a 5.07 percent increase over sales of $76.488 million the same period last year.

MLNK

MeridianLink Q3 2024 Adj. EPS $0.06 Misses $0.08 Estimate, Sales $80.369M Beat $79.969M Estimate

Boundless Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BOLD#NASDAQ">BOLD</a>) reported quarterly losses of $(0.74) per share which beat the analyst consensus estimate of $(0.82) by 9.76 percent.

BOLD

Boundless Bio Q3 2024 GAAP EPS $(0.74) Beats $(0.82) Estimate

Sports betting and iGaming company DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) reported third-quarter financial results<a href="https://www.benzinga.com/earnings"> after market close Thursday.</a>
Here are the key highlights.
What Happened: DraftKings reported third-quarter revenue of $1.095 billion, up 39% year-over-year. The revenue total missed a Street consensus estimate of $1.112 billion according to data <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110724&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
The company said revenue growth came from strong customer engagement, the acquisition of new customers, the launch in new territories, and the impact of the acquisition of Jackpocket, which closed in May.
The company reported a loss of 17 cents per share, which beat a Street consensus estimate of a loss of 42 cents per share.
Monthly unique payers (MUP) were 3.6 million in the third quarter, up 55% year-over-year. Excluding the impact of the Jackpocket acquisition, monthly unique payers would have been up 27% year-over-year.
The average revenue per MUP was $103 in the third quarter, down 10% year over year. The lower revenue per payer was due to the Jackpocket acquisition. Excluding the Jackpocket acquisition, the average revenue per MUP was 8% higher year over year.
"DraftKings delivered strong performance in the third quarter with the return of NFL and college football," DraftKings CEO Jason Robins said.
DraftKings was live for mobile sports betting in 25 states and Washington D.C., representing 49% of the U.S. population in the third quarter. The company is also live with iGaming in five states and live for both sportsbook and iGaming in Ontario, Canada.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/41792879/draftkings-q3-earnings-highlights-nfl-in-focus-will-missouri-legalization-factor-in">DraftKings Q3 Earnings Preview: NFL In Focus, Will Missouri Legalization Factor Into Guidance?</a>
What's Next: The company lowered its fiscal year 2024 revenue guidance from a range of $5.05 billion to $5.25 billion to a new range of $4.85 billion to $4.95 billion due to customer-friendly sport outcomes in the fourth quarter, which comes with the NFL season having several weeks of favorable outcomes for bettors.
Analysts expect the company to report revenue of $5.14 billion for the full fiscal year, according to data from Benzinga Pro.
The company also revised its 2024 adjusted EBITDA guidance from a range of $340 million to $420 million to a new range of $240 million to $280 million.
DraftKings introduced fiscal year 2025 revenue guidance for the first time, with a range of $6.2 billion to $6.6 billion expected. The company also said it expects 2025 adjusted EBITDA to be in a range of $900 million to $1.0 billion, reaffirming guidance from August.
"With major sports converging on the calendar, we are well-positioned to build on this momentum as we further enhance our top-ranked sportsbook app with additional live betting features and exciting new NBA markets," Robins said. "Our focus remains on driving sustainable revenue growth and profitability in 2025 and beyond."
The company's 2024 and 2025 guidance includes all existing mobile sports betting and iGaming markets and Jackpocket, but does not include any pending state launches.
Missouri legalized sports betting on Election Day 2024 and DraftKings expects to launch its sportsbook in the state pending approval. The company also expects to launch its sportsbook in Puerto Rico, which is pending approval.
DKNG Price Action: DraftKings stock is down 5% to $37.00 in after-hours trading Thursday, versus a 52-week trading range of $28.69 to $49.57.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/politics/24/11/41725070/draftkings-offers-10k-in-prizes-for-2024-election-predictions-harris-trump-swing-state-performan">DraftKings Offers $10K In Prizes For 2024 Election Predictions: Harris, Trump Swing State Performance Among Key Questions</a></li>
</ul>
Photo: Shutterstock

Sports Betting

Movers

Trading Ideas

DKNG

DraftKings Q3 Highlights: Revenue Miss, 2024 Guidance Trim, First 2025 Outlook, CEO Reaffirms Focus On 'Sustainable Revenue Growth'

QRHC

Quest Resources shares are trading higher after the company reported better-than-expected Q3 adjusted EPS results.

Eventbrite (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EB#NYSE">EB</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.13) by 69.23 percent. This is a 60 percent increase over losses of $(0.10) per share from the same period last year. The company reported quarterly sales of $77.80 million which beat the analyst consensus estimate of $75.83 million by 2.60 percent. This is a 4.59 percent decrease over sales of $81.54 million the same period last year.

Eventbrite Q3 EPS $(0.04) Beats $(0.13) Estimate, Sales $77.80M Beat $75.83M Estimate

Celularity receives Nasdaq notice regarding late Form 10-K filing

Catalyst Watch: AI in the spotlight with Nvidia earnings, Microsoft Build, and an IBM event

Celularity announces receipt of Nasdaq notice regarding late Form 10-Q filing

Celularity (CELU) has shared an update. Marc Mazur, a key board member of Celularity, has announced his resignation, effective July 31, 2024. His d...

Celularity Board Member Marc Mazur Announces Resignation

Celularity receives Nasdaq notice regarding late Form 10-Q filing

The latest announcement is out from Celularity (CELU). Celularity Inc. has announced the appointment of Richard J. Berman as a Class II director, f...

Celularity Announces Board Changes and New Indemnification Agreement

Celularity acquires Rebound product from Sequence Lifescience

Celularity receives Nasdaq notice, intends to file appeal

Celularity (CELU) issued a Corporate Update to Shareholders from Robert Hariri, Founder, Chairman, and CEO, which read in part, "Let me start by re...

Celularity to submit 510(k) notification for Tendon Wrap in early 2025

Celularity (CELU) has requested a hearing before the Nasdaq Hearings Panel the Nasdaq Listing Qualifications Department's determination regarding C...

Celularity files amended compliance plan with Nasdaq Hearings Panel

AAUKF

BYDDF

CELU

CELUW

DELL

DTRUY

MSFT

NGLOY

NKLA

NVDA

PANW

RIVN

SUPN

TMUS

TSLA

Press Releases

Celularity Presents Data of The Effect of Its T-Cell Platform on Multiple Hematological And Solid Tumors at the American Society of Clinical Oncology (ASCO) Annual Meeting

Celularity Reports Full Year 2023 Combined Net Sales of $22.8 Million, a 26.7% Increase Over Full Year 2022, and Announces First Half 2024 Expected Combined Net Sales of $26.9 Million Representing 290% Growth Over First Half 2023

Celularity Inc. Announces Receipt of Nasdaq Notice Regarding Late Form 10-Q Filing

Management

Celularity Appoints Richard J. Berman to its Board of Directors

Celularity to Present at H.C. Wainwright's 26th Annual Global Investment Conference

Celularity Expands Advanced Biomaterial Product Commercial Portfolio with Acquisition of Rebound™ Product from Sequence LifeScience, Inc.

Markets

Celularity Inc. Receives Notice from Nasdaq; Confirms Intention to File an Appeal

Celularity Provides Corporate Update

Celularity Files Appeal Request and Amended Compliance Plan with Nasdaq Hearings Panel

Celularity Raises Full Year 2024 Guidance as Expected Net Sales Through October Reach $44.4 Million

Acurx Pharmaceuticals, Inc. - Common Stock

Acurx Pharmaceuticals

AEON Biopharma, Inc. Class A Common Stock

AEON Biopharma

Akari Therapeutics Plc - American Depositary Shares

Akari Therapeutics

Aligos Therapeutics

BioLineRx Ltd. - American Depositary Shares

BioLine Rx

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

BioXcel Therapeutics, Inc. - Common Stock

BioXcel Therapeutics

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Dyadic International, Inc. - Common Stock

Dyadic International

Elevation Oncology

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroGen

Fresh2 Group Limited - American Depositary Shares

Fresh2 Group

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

ImmuCell

MiNK Therapeutics

Longeveron

Lantern Pharma

Lumos Pharma

Marker Therapeutics

NextCure

Ocean Biomedical

SAB Biotherapeutics

Surrozen

vTv Therapeutics Inc. - Class A Common Stock

Comments

Celularity

Actualités

Dernières nouvelles pour Celularity (NASDAQ:CELU) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL